Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells
Hiroki Yokota¹,2*, Kazunori Hamamura¹, Andy Chen¹, Todd R Dodge¹, Nancy Tanjung¹, Aysan Abedinpoor¹ and Ping Zhang¹,2,3*

Abstract
Background: Osteoporosis is a skeletal disease leading to an increased risk of bone fracture. Using a mouse osteoporosis model induced by administration of a receptor activator of nuclear factor kappa-B ligand (RANKL), salubrinal was recently reported as a potential therapeutic agent. To evaluate the role of salubrinal in cellular fates as well as migratory and adhesive functions of osteoclast/osteoblast precursors, we examined the development of primary bone marrow-derived cells in the presence and absence of salubrinal. We addressed a question: are salubrinal’s actions more potent to the cells isolated from the osteoporotic mice than those isolated from the control mice?

Methods: Using the RANKL-injected and control mice, bone marrow-derived cells were harvested. Osteoclastogenesis was induced by macrophage-colony stimulating factor and RANKL, while osteoblastogenesis was driven by dexamethasone, ascorbic acid, and β-glycerophosphate.

Results: The results revealed that salubrinal suppressed the numbers of colony forming-unit (CFU)-granulocyte/macrophages and CFU-macrophages, as well as formation of mature osteoclasts in a dosage-dependent manner. Salubrinal also suppressed migration and adhesion of pre-osteoclasts and increased the number of CFU-osteoblasts. Salubrinal was more effective in exerting its effects in the cells isolated from the RANKL-injected mice than the control. Consistent with cellular fates and functions, salubrinal reduced the expression of nuclear factor of activated T cells c1 (NFATc1) as well as tartrate-resistant acid phosphatase.

Conclusions: The results support the notion that salubrinal exhibits significant inhibition of osteoclastogenesis as well as stimulation of osteoblastogenesis in bone marrow-derived cells, and its efficacy is enhanced in the cells harvested from the osteoporotic bone samples.

Keywords: Osteoporosis, RANKL, Salubrinal, Osteoclasts, Osteoblasts

Background
Osteoporosis is a common skeletal disease of bone loss, which leads to an increased risk of bone fractures, morbidity, mortality, and an economic burden to society [1-3]. In many cases it is a physiological consequence of the aging process [3,4], and in postmenopausal women it is induced by a decrease in the production of estrogen, a hormone known to maintain the appropriate ratio of bone-forming osteoblasts to bone-resorbing osteoclasts [5]. During the past 20 years, many therapeutic drugs have been developed to prevent osteoporotic bone loss. Bisphosphonates are the most widely prescribed medications to treat postmenopausal osteoporosis, but they may be associated with an increased risk of osteonecrosis of the jawbone and atypical femur fracture [6]. Other treatments include administration of estrogen and estrogen analogs, as well as parathyroid hormone. However, increased risks of breast cancers and blood clots have been reported as side effects of these treatments [7-9]. The aim of this study is to evaluate a therapeutic role of a chemical agent, salubrinal, in potential treatment of osteoporosis.

Salubrinal is a small chemical agent (480 Da, C₂₁H₁₇Cl₃N₄OS) known to block de-phosphorylation of
eukaryotic translation initiation factor 2 alpha (eIF2α) [10]. Salubrinal is also reported to attenuate molecular signaling mediated by nuclear factor kappa B (NFκB) [11]. The elevated phosphorylation level of eIF2α upregulates activating transcription factor 4 (ATF4), one of the key transcription factors in bone formation [12]. Salubrinal is shown to enhance healing of bone wounds and promotes differentiation of osteoblasts [13]. Little is known, however, about its effects on bone resorption, in particular developmental regulation of bone marrow-derived cells. Bone marrow-derived cells contain mesenchymal stem cells (MSCs) and hematopoietic stem cells that give rise to osteoblasts and osteoclasts, respectively [14]. The primary focus of this study is the potential role of salubrinal in the development of bone marrow-derived cells towards mature osteoclasts, as well as its role in development of mesenchymal stem cells and osteoblasts.

Experimental animal models are useful to evaluate therapeutic efficacy of chemical agents. Available osteoporosis models include ovariectomy (OVX) [15,16], tail suspension [17,18], denervation [19,20], a low-calcium diet [21,22], and administration of receptor activator of nuclear factor kappa-B ligand (RANKL) [23-25]. Any animal model may have its advantage and disadvantage. For instance, OVX-induced osteoporosis, which is currently considered as the gold standard for the evaluation of pharmaceuticals for postmenopausal osteoporosis, not only reduces the level of estrogen but also generates surgery-induced injury together with an increase in osteoblast activity. Furthermore, surgical induction of OVX requires consistency in the surgical procedure as well as a minimum of 4 weeks. The tail suspension model not only increases bone resorption but also reduces osteoblast differentiation. In the denervation model, surgery-induced injury is involved. In this study, we evaluated in vivo effects of salubrinal using the OVX mice and in vitro effects of salubrinal using bone marrow-derived cells isolated from the RANKL-injected mice.

In the RANKL administration model, RANKL is subcutaneously injected for a short period as 3 days [26]. RANKL is a cytokine belonging to the tumor necrosis factor family. In the immune system, it is involved in dendritic cell maturation, while in the skeletal system it is a ligand for osteoprotegerin (OPG) and functions as a key regulator for osteoclast differentiation and activation [27,28]. RANKL deletion in mice leads to osteopetrosis and a decrease of osteoclasts, while RANKL overproduction is linked to a variety of degenerative bone diseases including osteoporosis and rheumatoid arthritis [29,30].

Focusing on the development of bone marrow-derived cells in the presence and absence of salubrinal, we addressed a pair of questions: Does administration of salubrinal modulate cellular fates and functions of bone marrow-derived cells in favor of prevention of bone loss? If so, are salubrinal’s actions more potent to the cells isolated from the osteoporotic RANKL-injected mice than those isolated from the control mice? Because of the anticipated role of salubrinal that is potentially opposite to that of RANKL, we hypothesized that salubrinal is more effective in inhibiting development of osteoclasts and stimulating development of osteoblasts in the cells isolated from the RANKL-injected mice than those from the control mice. To test the hypothesis, we employed assays such as colony-forming unit - granulocyte/macrophages (CFU-GM), colony-forming unit - macrophages (CFU-M), and formation of multi-nucleated osteoclasts in an osteoclast differentiation medium, as well as assays for migration and adhesion of pre-osteoclasts. We also conducted assays for examining colony-forming unit – osteoblasts (CFU-OBL) in an osteoblast differentiation medium. To evaluate salubrinal’s effects on expression of nuclear factor of activated T cells c1 (NFATc1), a master transcription factor for osteoclastogenesis, we conducted real-time PCR and Western blot analysis.

Methods

Animals and materials preparation

C57BL/6 female mice (7 weeks of age) were used. Each cage housed four to five mice at the Indiana University Animal Care Facility. They were fed with mouse chow and water ad libitum. Experimental procedures were approved by the Indiana University Animal Care and Use Committee and were in compliance with the Guiding Principles in the Care and Use of Animals endorsed by the American Physiological Society. Cytokines were purchased from PeproTech (Rocky Hills, NC, USA) and other chemicals from Sigma (St. Louis, MO, USA) unless otherwise stated. Salubrinal (R&D Systems, Minneapolis, MN, USA) was administered at 1 mg/kg to mice, and at 0.5 to 5 μM to cultured cells for the duration of each experiment.

Ovariectomy

The animal was anesthetized with 1.5% isoflurane at a flow rate of 0.5 to 1.0 L/min. After removing the hair, the skin at the operative sites was cleaned using 70% alcohol and 10% providoneiodine solution. An incision (~20 mm) was made at the midline dorsal skin, and the peritoneal cavity was incised to access the ovaries. After removing the ovaries, the wound was closed by suturing. In 4 weeks after surgery, subcutaneous injection of salubrinal was conducted daily at a dose of 1 mg/kg body weight for 4 weeks. The control OVX mice received an equal volume of vehicle.

RANKL administration for the bone loss model

Soluble recombinant murine RANKL (sRANKL; PeproTech) was injected subcutaneously using a 1 mg/kg dosage in 100 μl PBS at 24 h intervals for 3 days [26]. The same
volume of PBS was injected into vehicle control mice. At 90 min after the final injection, the mice were euthanized. Iliac bones, femora, and tibiae were harvested, and bone marrow-derived cells were collected.

**Determination of bone mineral density (BMD) and bone mineral content (BMC)**

The BMD (g/cm²) and BMC (g) of an entire humerus and ulna were determined using peripheral dual energy X-ray absorptiometry (DXA; PiXimus II, Lunar Corp., Madison, WI, USA) and its software (version 1.47).

**Colony-forming unit-granulocyte-macrophages (CFU-GM) assay**

As previously described, a colony-forming unit-granulocyte-macrophage (CFU-GM) assay was conducted [31-33]. Approximately 2.5x10⁴ bone marrow-derived cells were prepared from the vehicle control and RANKL-treated mice and seeded onto a 35-mm gridded dish composed of methylcellulose supplemented with 30 ng/ml murine macrophage-colony stimulating factor (M-CSF), and 20 ng/ml RANKL. Three dosages of salubrinal (1, 2, and 5 μM) were administered, and cells were cultured at 37°C in a 5% CO₂ incubator for 7 days.

**Colony-forming unit-macrophage/mononuclear (CFU-M) assay**

Using bone marrow mononuclear cells (BMMNCs), a colony-forming unit-macrophage/mononuclear (CFU-M) assay was conducted, as described previously [34-37]. From the vehicle control and RANKL administration mice, approximately 2.5x10⁴ bone marrow-derived cells were prepared. Cells were seeded onto a 35-mm gridded dish, which was composed of methylcellulose supplemented with 30 ng/ml M-CSF and 20 ng/ml RANKL. Three dosages of salubrinal (1, 2, and 5 μM) were administered, and cells were cultured at 37°C in a 5% CO₂ incubator for 7 days.

**Isolation of bone marrow-derived cells for osteoclast development**

Bone marrow-derived cells were collected by flushing the iliac, femur and tibia with Iscove's MEM (Gibco-Invitrogen, Carlsbad, CA, USA) containing 2% fetal bovine serum using a 23-gauge needle, as described previously [34,38]. Low-density gradient centrifugation was used to separate the cells, which were then cultured in α-MEM supplemented with 10% FBS, 30 ng/ml M-CSF, and 20 ng/ml murine receptor activator of nuclear factor kappa-B ligand (RANKL). Culture medium was replaced by α-MEM supplemented with 10% FBS, 30 ng/ml M-CSF, and 60 ng/ml RANKL on the third day, and cells were then grown for an additional 3 days.

**Osteoclast differentiation assay**

Using bone marrow-derived cells isolated from the vehicle control and RANKL-treated mice with administration of salubrinal (0, 1, 2, and 5 μM) in 96-well plates, an osteoclast differentiation assay was performed, as described previously [34,39,40]. For one experimental condition, salubrinal was applied on day 0 to day 6 (6 days), while in the other experimental condition, it was applied on day 4 to day 6 (3 days). Culture medium was exchanged once on day 4 during the 6-day experiments. A tartrate resistant acid phosphate (TRACP)-staining kit was used according to the manufacturer's instructions to fix and stain adherent cells. TRACP-positive multinuclear cells (> 3 nuclei) were identified as osteoclasts, and their numbers were counted [39]. The osteoclast formation assay was performed at least 3 times using cells isolated independently from different cohorts of mice.

**Osteoclast migration assay**

Using a transwell assay, migration of osteoclasts was evaluated as described previously with minor modifications [41]. After isolating them from vehicle control and RANKL-treated mice, bone marrow-derived cells (2 × 10⁵/ml) were cultured in M-CSF and RANKL in 6-well plates for 4 days, and then trypsinized in Hank's balanced salt solution. With and without salubrinal (2 μM), the osteoclast precursor cells (1 × 10⁴ cells/well) were loaded onto the upper chamber of transwells and allowed to migrate to the bottom chamber through an 8-μm polycarbonate filter coated with vitronectin (Takara Bio Inc., Otsu, Shigma, Japan). α-MEM consisting of 1% bovine serum albumin (BSA) and 30 ng/ml of M-CSF was in the bottom chamber. After reacting for 6 h, the osteoclast precursor cells in the lower chamber was stained with crystal violet and counted.

**Osteoclast adhesion assay**

Ninety-six well plates were coated with 5 μg/ml vitronectin in α-MEM supplemented with 30 ng/ml M-CSF and were applied with osteoclast precursors (1 × 10⁵ cells/well) in the presence and absence of salubrinal (2 μM), as described previously [41]. Cells were incubated for 30 min, then washed with PBS three times and fixed with 4% paraformaldehyde at room temperature for 10–15 min. After crystal violet staining, the number of cells adherent to αvβ₃ integrin was counted.

**Osteoblast differentiation assay**

Bone marrow-derived cells were plated at 2 × 10⁶/ml in 6-well plates in osteogenic differentiation medium (MesenCult proliferation kit) supplemented with 10 nM dexamethasone, 50 μg/ml ascorbic acid 2-phosphate, and 10 mM β-glycerophosphate to induce osteogenic differentiation, as described previously [39,41,42]. Cells were
cultured for 2 weeks in the presence and absence of salubrinal (0.5 μM), and medium was changed every other day. For alkaline phosphatase (ALP) staining, cells were fixed in citrate-buffered acetone for 30 s, incubated in the alkaline-dye mix for 30 min, and counterstained with Mayer’s Hematoxylin for 10 min. Cells were then evaluated microscopically and the intensity of ALP staining was determined.

To evaluate the effects of RANKL administration on multiple developmental stages starting from bone marrow-derived cells to mature osteoclasts, the RANKL-driven alterations in CFU-GM, CFU-M, osteoclast formation, migration, and adhesion were determined as fold-changes of the RANKL-injected mice to the vehicle control mice. Furthermore, to quantify efficacy of salubrinal in various developmental stages in osteoclastogenesis, the degree of suppression was measured with reduction ratios between the samples treated with and without 2 μM salubrinal.

Expression analysis of NFATc1 in bone marrow-derived cells and RAW264.7 pre-osteoclast cells

For Western blot analysis, RAW264.7 mouse monocyte/macrophage cells (ATCC, Manassas, VA, USA) were grown in α-MEM containing 10% fetal bovine serum and antibiotics (50 units/ml penicillin, and 50 μg/ml streptomycin; Life Technologies, Grand Island, NY, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA). Antibodies specific to NFATc1 (Santa Cruz), and β-actin (Sigma) were employed. Protein levels were assayed using a SuperSignal west femto maximum sensitivity substrate (Thermo Scientific). The bands were scanned with Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and phosphatase inhibitors (Calbiochem, Billerica, MA, USA).

TRACP is highly expressed in osteoclasts, we used its mRNA expression level as a marker for development of osteoclasts. The relative mRNA abundance for the selected genes with respect to the level of GAPDH mRNA was expressed as a ratio of Strated/Scontrol where Strated is the mRNA level for the cells treated with salubrinal, and Scontrol is the mRNA level for control cells.

Statistical analysis

The data were expressed as mean ± standard error of mean (SEM). Student’s t-test was conducted for two-group comparisons. For many-group comparisons, one-way ANOVA was used, followed by a post-hoc test using Fisher’s protected least significant difference. All comparisons were two-tailed, and statistical significance was assumed at p < 0.05. The asterisks (*, **, and ****) represent p < 0.05, p < 0.01, and p < 0.001, respectively.

Results

Evaluation of BMD and BMC of the OVX mice and RANKL-injected mice

Four-week daily administration of salubrinal at a dose of 1 mg/kg to the OVX mice significantly elevated both BMD and BMC of a whole body (Figure 1A-B). Three-day administration of RANKL at a dose of 1 mg/kg, however, significantly decreased BMD and BMC of the humerus and ulna (N = 6; both p < 0.05) (Figure 1C-D). Using the RANKL-injected mice, bones from the iliac, femora, and tibiae were harvested. Bone marrow-derived cells were collected from those bones for examining the effects of salubrinal on developments of osteoclasts and osteoblasts.

Reduction in the number of CFU-GM by salubrinal in a dosage-dependent manner

To determine the effects of salubrinal on the proliferation of osteoclast progenitors, the CFU-GM assay was conducted using bone marrow-derived cells isolated from the RANKL-injected mice. Salubrinal at 1, 2, and 5 μM reduced the total number of CFU-GM in the femur in a dosage-dependent manner (p < 0.05 for 1 μM salubrinal; p < 0.01 for 2 μM; and p < 0.001 for 2 & 5 μM) in the RANKL-injected mice (Figure 2A). The CFU-GM numbers were 37,177 ± 1,919 (vehicle control) and 53,213 ± 3,545 (RANKL administration, p < 0.001) (Figure 2B). The CFU-GM numbers were reduced by administration of salubrinal at 2 μM for 7 days by 28.5% (p < 0.001) in vehicle control and 30.8% (p < 0.001) in the RANKL-injected mice.

Reduction in the number of CFU-M by salubrinal in a dosage-dependent manner

To determine the effects of salubrinal on the population of osteoclast progenitors, the CFU-M assay was performed using bone marrow-derived cells isolated from the
RANKL-injected mice. Consistent with the CFU-M numbers, administration of salubrinal at 1, 2, and 5 μM reduced the total number of CFU-M in the femur in a dosage-dependent manner (all \( p < 0.001 \) in three dosages) (Figure 3A). The CFU-M numbers were 10,602 ± 396 (vehicle control) and 18,648 ± 760 (RANKL administration, \( p < 0.001 \)) (Figure 3B). Administration of salubrinal at 2 μM for 7 days, for instance, reduced the CFU-M number by 41.2% (\( p < 0.001 \)) in vehicle control and 43.1% (\( p < 0.001 \)) in the RANKL-injected mice.

**Suppression of osteoclast differentiation by salubrinal in a dosage- and time-dependent manner**

Compared to the bone marrow-derived cells isolated from the vehicle control, the cells from the RANKL-injected mice exhibited an increase in the surface area occupied by multi-nucleated osteoclasts (24.8 ± 1.0% in vehicle control, and 36.5 ± 1.3% in RANKL administration) (Figure 4A). A series of images show that the process of osteoclast fusion was accelerated by administration of salubrinal. To evaluate the effects of salubrinal, three dosages of salubrinal (1, 2, and 5 μM) were applied. In the cultures salubrinal was applied on day 0 for 6 days, administration of salubrinal resulted in a significant decrease in the surface area covered by multi-nucleated osteoclasts for vehicle control (all \( p < 0.001 \)) and RANKL administration (all \( p < 0.001 \)) (Figure 4A). In the cultures salubrinal was applied on day 3 for 4 days, the reduction of the area was also observed (all \( p < 0.001 \)) (Figure 4B). A series of images indicate that the cellular fusion was reduced by salubrinal administration in a time-and dose-dependent manner.

To further evaluate potential effects of the period of salubrinal administration on osteoclast formation, we compared the results of two sets of experiments in which salubrinal at 2 μM was administered from days 0 to 6, and days 4 to 6. The result revealed that salubrinal administration at day 0 presented larger reduction in osteoclast formation than that at day 4 in the vehicle control and RANKL-injected groups (both \( p < 0.001 \)) (Figure 4C).

**Suppression of migration and adhesion of pre-osteoclasts by salubrinal**

Pre-osteoclast cells isolated from the RANKL-injected mice were more migratory (304.1 ± 12.2 cells) than those from the vehicle control (190.4 ± 5.9 cells, \( p < 0.001 \)), and the RANKL-driven increase was 37.4% (Figure 5A). However, salubrinal suppressed the amount of migration by 33.0% in vehicle control (\( p < 0.001 \)) and by 53.2% in RANKL administration (\( p < 0.001 \)). In the M-CSF mediated adhesion assay to αVβ3, the cells isolated from the RANKL-injected mice presented an increase in adhesion by 59.8% (142.5 ± 3.9 cells) over those from the vehicle control (57.3 ± 1.8 cells, \( p < 0.001 \)) (Figure 5B). Administration of salubrinal presented significant reduction in cell adhesion by 32.4% in vehicle control (\( p < 0.001 \)) and by 53.7% in RANKL administration (\( p < 0.001 \)).
Promotion of osteoblast differentiation by salubrinal

In the CFU-OBL assay, a significant increase in the number of ALP positive cells was detected by administration of salubrinal. Without salubrinal, the percentage of ALP-positive cells was 18.3 ± 2.3% in vehicle control and 20.4 ± 2.0% in RANKL administration (p < 0.001) (Figure 6).

Administration of salubrinal at 0.5 μM increased the percentage of ALP-positive cells to 23.5 ± 1.1% in vehicle control (p < 0.05) and 28.8 ± 2.3% in RANKL administration (p < 0.01) (Figure 6).

Downregulation of NFATc1 by salubrinal in bone marrow-derived cells and RAW264.7 pre-osteoclast cells

Bone marrow-derived cells were incubated with RANKL in the presence and absence of salubrinal. Incubation with 20 ng/ml RANKL markedly increased the level of NFATc1, a master transcription factor for development of osteoclasts, and administration of 1 μM salubrinal
reduced the RANKL-driven increase in NFATc1 by 24% (Figure 7A). To further evaluate the effects of salubrinal, we employed RAW264.7 pre-osteoclast cells. Administration of 20 ng/ml RANKL elevated the level of NFATc1, and in response to 1–20 μM salubrinal the RANKL-induced elevation of NFATc1 was reduced in a dose dependent fashion (Figure 7B). Furthermore, the mRNA levels of NFATc1 and TRACP were increased by RANKL, and their elevation was suppressed by administration of salubrinal (Figure 7C).

**Discussion**

The present study presents the beneficial effect of *in vivo* administration of salubrinal on BMD and BMC of the OVX mice, and *in vitro* effects on the culture of bone marrow-derived cells isolated from the RANKL-injected and control mice. In the osteoclast assays of CFU-GM, CFU-M, and formation of multi-nucleation, salubrinal significantly reduced the numbers of osteoclastic colonies and cells isolated from both the vehicle control and RANKL-injected mice. In the two sets of maturation...

---

**Figure 4 Effects of administration of salubrinal on multi-nucleated osteoclast formation.** Using bone marrow-derived cells isolated from the vehicle control and RANKL-treated mice, an osteoclast differentiation assay was performed. The culture medium was exchanged once on day 4 during the 6-day experiments. TRACP-positive multinuclear cells (> 3 nuclei) were identified as osteoclasts. The areas covered by multi-nucleated osteoclasts are quantified in response to 3 doses of salubrinal (1, 2, and 5 μM). The microphotographs represent the two groups of osteoclast cultures (vehicle control and RANKL administration) with TRACP staining. Bar = 200 μm. A: Area covered by multi-nucleated osteoclasts in response to *in vitro* administration of salubrinal from day 0 to day 6 (6 days). B: Area covered by multi-nucleated osteoclasts in response to *in vitro* administration of salubrinal from day 4 to day 6 (3 days). C: Fold change in response to 2 μM salubrinal.
assays, in which salubrinal was applied from day 0 to 6 and from day 4 to 6, it suppressed both the early and late stages of osteoclastogenesis. This suppressive effect was larger in the cells isolated from the RANKL-injected mice than the vehicle control mice. In addition to attenuating osteoclastogenesis, salubrinal was able to reduce adhesion and migration of osteoclasts. Furthermore, it increased the number of CFU-OBL colonies suggesting that it not only inhibits development of osteoclasts but also promotes development of osteoblasts. Quantitative PCR and Western blot analysis revealed that the mRNA and protein levels of NFATc1 were elevated by RANKL, and this elevation was suppressed by administration of salubrinal in a dose dependent fashion.

In evaluating the effects of salubrinal on fates of HSCs and MSCs in bone marrow-derived cells, we employed the recently developed RANKL administration model of osteoporosis. An advantage of this RANKL administration model includes a short period (3 days in this study) for induction of osteoclastogenesis, and activation of multiple steps in the development of osteoclasts. In the RANKL/OPG signaling pathway, RANKL regulates not only development of osteoclasts but also their activation and survival [43]. RANKL is expressed in bone, bone marrow, and lymphoid tissues including spleen that houses osteoclast precursor cells as macrophages [44]. The RANKL administration model provided a platform to
evaluate efficacy of salubrinal as a potential therapeutic agent for preventing osteooclasis and bone resorption. Besides bone resorption, however, RANKL is involved in multiple functions in the immune system such as proliferation of T cells and inhibition of apoptosis of dendritic cells [45]. It is reported that overproduction of RANKL induces inflammatory bone disorders [46,47]. Thus, the results from any animal model including the RANKL administration model should be confirmed by other animal models and eventually clinical trial.

The regulatory mechanism of salubrinal’s action on osteooclasis is not well understood. Salubrinal is known as an inhibitor of serine/threonine-protein phosphatase PPI and it elevates the phosphorylation level of eIF2α (eIF2α-p) [48]. The level of eIF2α-p is upregulated in response to various stresses including viral infection, nutrient deprivation, radiation, and stress to the endoplasmic reticulum [49]. To cope with these cellular insults and reduce apoptosis, the elevated eIF2α-p in general lowers ribosome’s efficiency of protein synthesis except for a group of proteins such as ATF4. Applications of salubrinal have been reported to reduce stress induced apoptosis [50]. We have previously shown that partial silencing of eIF2α by RNA interference reduces salubrinal-driven downregulation of NFATc1 in RAW264.7 cells [51], and the results in this study indicate that mRNA and protein expression of NFATc1 is downregulated by salubrinal. NFATc1 is a member of the NFAT transcription factor family and a master transcription factor for osteoclasis development. It is reported that NFATc1-deficient embryonic stem cells are unable to differentiate into osteoclasts [52]. He et al. has recently shown that NFATc1 expression is regulated at a translational stage in bone marrow macrophage cells, and a phosphorylation mutant plasmid for eIF2α restored RANKL-induced NFATc1 expression [53]. MaB (V-maf musculoaponeurotic fibrosarcoma oncogene homolog B), IRF8 (interferon regulatory factor 8), and Bcl6 (V cell lymphoma) have been mentioned as inhibitors of NFATc1 [54-56]. Further analysis is necessary for identification of the mechanism of salubrinal’s action on NFATc1, which is possibly regulated by eIF2α alone or any other mediators.

Conclusions

It is premature to draw any conclusion on development of a potential therapeutic agent for treatment of osteoporosis, but salubrinal possesses several unique features. First, it is a small synthetic chemical agent, which can be taken as an oral pill. Second, it has a dual role of stimulation of bone formation and attenuation of bone resorption. Third, its effects are stronger in the cells isolated from the osteoporotic RANKL-injected mice than those from the control mice. Fourth, it presents dose dependent efficacy in preventing osteooclasis throughout a developmental stage including proliferation, multi-nucleation, and maturation, as well as migration and adhesion. The results herein support the possibility of preventing bone loss through salubrinal-driven regulation of bone marrow-derived cells.

Abbreviations

O VX: Ovariectomy; BMD: Bone mineral density; BMC: Bone mineral content; eIF2α: Eukaryotic translation initiation factor 2 alpha; eIF2α-p: Phosphorylated eIF2α; NFκB: Nuclear factor kappa B; ATF4: Activating transcription factor 4; NFATc1: Nuclear factor of activated T cells c1; OPG: Osteoprotegerin; RANKL: A Receptor activator of nuclear factor kappa-B ligand; M-CSF: Murine macrophage-colony stimulating factor; BM-MSCs: Bone marrow mononuclear cells; MSCs: Mesenchymal stem cells; CFU-M: Colony forming-unit macrophages; CFU-GM: Colony forming-unit granulocyte/macrophages; CFU-ML: Colony forming-unit – osteoblasts; ALP: Alkaline phosphatase; TRACP: Tartrate resistant acid phosphate; BSA: Bovine serum albumin.

Competing interests

The authors declare that they have no competing interests.
Authors’ contributions
HY participated in experimental designs, and drafted a manuscript. KH conducted molecular experiments, performed data collection and analysis. AC and TD conducted animal experiments. NT and AA assisted data collection. PZ participated in experimental designs, performed animal and cell experiments. Ots; conducted data collection and interpretation, and drafted a manuscript. PZ accepted responsibility for integrity of data analysis. All authors read and approved the final manuscript.

Acknowledgements
The authors appreciated Enlin Qian for technical support.

Author details
1Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, 723 West Michigan Street, SL220, Indianapolis, IN 46202, USA.
2Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
3School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300072, People’s Republic of China.

Received: 26 April 2013 Accepted: 14 June 2013
Published: 1 July 2013

References
1. van den Bergh JP, van Geel TA, Geuens PP: Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol 2012, 8:163–172.
2. Saito M, Kuroda T, Miyakawa N, Fujisawa N, Tanzawa K, Ishizu A, Tanaka S, Tanaka Y, Hosoi T, Itoi E, Morimoto S, Ibashiki A, Sugimoto T, Yamashita T, Gorai L, Moris K, Ishihara H, Mizumura H, Endo N, Nishiyama Y, Takaoka K, Ohashi Y, Ohta F, Fukunaga M, Nakamura T, Orimo H: Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOIN) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-STOP). J Bone Miner Metab 2011, 29:37–43.
3. Vercini F, Grimaldi F: PTH 1–84: bone rebuilding as a target for the therapy of severe osteoporosis. Clin Cases Miner Bone Metab 2012, 9:31–36.
4. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A: Role of RANKL ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 2012, 34:521–536.
5. Yang Q, Jian J, Abraham SB, Huang X: Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res 2011, 26:1188–1196.
6. Khosla S, Blezak JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shae H, Shoback D, Potts JT: Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012, 97:2272–2282.
7. Riggs BL, Khosla S, Melton LJ III: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:792–799.
8. Valverde F: Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008, 15:284–304.
9. Boras-Ganic K, Wysołomski J: PTH/ PTHrP and breast cancer: more than hypercalcemia and bone metastases. Breast Cancer Res 2012, 14:307.
10. Boyce M, Bryant AF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RI, Ma D, Coen DM, Ron D, Yuan J: A selective inhibitor of elf2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:235–239.
11. Huang X, Chen Y, Zhang H, Ma Q, Zhang Y, Xu H: Salubrinal attenuates β-amylloid-induced neuronal death and microglial activation by inhibition of the NF-κB pathway. Neurobiol Aging 2012, 33:1006.97–1006.117.
12. Saito A, Ochiai K, Kondo S, Tsunagari K, Murakami T, Cavenar DR, Imaizumi K: Endoplasmic reticulum stress response mediated by the PERK-elf2α (alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem 2011, 286:4809–4818.
13. Zhang P, Hamamkura K, Jiang C, Zhang L, Yokota H: Salubrinal promotes healing of surgical wounds in rat femurs. J Bone Miner Metab 2012, 30:566–579.
14. Li X, Ling W, Khan S, Yacoby S: Therapeutic effects of intrabone and systemic mesenchymal stem cell cytophoresis on myeloma bone disease and tumor growth. J Bone Miner Res 2012, 27:1635–1648.
15. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavsky BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffer MB, Moonga BS, Blair HC, Zaidi M: FSH directly regulates bone mass. Cell 2012, 150:247–263.
16. Weitzmann MN, Pacifi R: Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006, 116:1186–1194.
17. Shahnazari M, Wonski T, Chy V, Williams A, Laperre A, Stollina M, Ke HZ, Halloran E: Early response of bone marrow osteosclerotic progenitors to skeletal unloading and sclerostin antibody. Calcif Tissue Int 2012, 91:30–38.
18. Zhang P, Hamamkura K, Yokota H: A brief review of bone adaptation to unloading. Genomics Proteomics Bioinform 2009, 6:4–7.
19. Gaspar AP, Lazarret-Castro M, Brandão CM: Bone mineral density in spinal cord injury: an evaluation of the distal femur. J Osteoporos 2012, 2012:519754.
20. Jiang SD, Jiang LS, Dai LY: Mechanisms of osteoporosis in spinal cord injury. Clin Endocrinol (Oxf) 2012, 65:555–565.
21. Omi N, Ezawa I: Animal models for bone and joint disease. Low calcium diet-induced rat model of osteoporosis. Clin Calcium 2012, 21:73–180.
22. Chenmiah S, Vijayakshmi V, Suresh C: Effect of the supplementation of dietary rich phytoestrogens in altering the vitamin D levels in diet induced osteoporotic rat model. J Steroid Biochem Mol Biol 2010, 121:268–272.
23. Lo Jacano N, Blair HC, Pollani PL, Marevill F, Cicara B, Facchetti F, Fontana E, Guermi MM, Traggiai E,蕨 Dy F, Pauls M, Mantero S, Infzarto A, Valaperta S, Pangrazio A, Crisafulli L, Maina V, Kostenuk P, Vezzoni P, Villa A, Sobacchi C: Osteopetrosis rescue upon RANKL administration to Rank1(−/−) mice: A new therapy for human RANKL-dependent ARO. J Bone Miner Res 2012, 27:5301–5310.
24. Campbell GM, Ominsky MS, Boyd SK: Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. Osteoporos Int 2011, 22:931–942.
25. Yasuda H: Animal models for bone and joint disease. RANKL-injected bone loss model. Clin Calcium 2011, 21:197–208.
26. Tomimoto Y, Mor K, Koido M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H: Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res 2009, 24:1194–1205.
27. Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W: Serum osteoproteoglycan (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents. J Pediatr Endocrinol Metab 2009, 22:1099–1104.
28. Takayanagi H: Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2010, 5:467–476.
29. Nakamura M, Udagawa N: Osteoporosis and RANKL signal. Clin Calcium 2011, 21:1149–1155.
30. Pericot T, Penninger JM: Development and function of murine B cells lacking RANK. J Immunol 2012, 188:1201–1205.
31. Mun SH, Won HJ, Hernandez P, Aguil N, Lee SK: Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass. J Bone Miner Res 2013, 28:948–959.
32. Drexmeyer HE, Kappes F, Mor-Vaknin N, Legnende M, Kiraforg J, Cooper S, Hangoc G, Markovitz DM: DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Stem Cells Dev 2012, 21:1449–1454.
33. Koeppel JM, Pekovits K, Stievel I, Fuchs R, Zelber S, Hofmann F, Sedlmayr P, Doehr G, Wallner-Leibmann S, Dormy W, Muller W: Exercise increases the frequency of circulating hematopoietic progenitor cells, but reduces hematopoietic colony-forming capacity. Stem Cells Dev 2012, 21:2915–2925.
34. He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC: c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions. PLoS One 2012, 7:e69600.
35. Ren D, Gunarunurthy A, Wright M, Pfeifer TW, Loboa EG, Everett ET: Genetic background influences fluoride’s effects on osteostegal appe. Bone 2007, 41:1036–1114.
36. Broxmeier HE, Meja JA, Hangoc G, Barse C, Dinauer M, Cooper S: SDF-1/CXCL12 enhances in vitro reoplate capacity of murine and human multipotent and macrophage progenitor cells. Stem Cells Dev 2007, 16:589–596.
37. McHugh KP, Shen Z, Crotti TN, Flannery MR, Fajardo R, Bierbaum BE, Goldring SR. Role of cell-matrix interactions in osteoclast differentiation. Adv Exp Med Biol 2007, 602:107–111.

38. Wu X, Chen S, Orlando SA, Yuan J, Kim ET, Munugalavada V, Mali RS, Kapur R, Yang FC. p85α regulates osteoblast differentiation by cross-talking with the MAPK pathway. J Biol Chem 2011, 286:13512–13521.

39. Abdullah BM, Ditzel N, Mahmodoo A, Isa A, Traustadottir GA, Schilling AF, Ruiz-Hidalgo MJ, Laborda J, Amling M, Kassem M. DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice. J Bone Miner Res 2011, 26:1457–1471.

40. Jansen ID, Vemeer IA, Bloemen V, Steij J, Events V. Osteoclast fusion and fission. Calcif Tissue Int 2012, 90:515–522.

41. Xiao G, Cheng H, Cao H, Chen K, Tu Y, Yu S, Jiao H, Yang S, Im HJ, Chen D, Chen J, Wu C. Critical role of filamin-binding LIM protein 1 (FBLP-1)/migfilin in regulation of bone remodeling. J Biol Chem 2012, 287:21450–21460.

42. Nabavi N, Khandani A, Camirand A, Harrison RE. The RANKL/RANK/OPG pathway. J Bone Miner Res 2010, 25:2469–2469.

43. Boyce BF, Xing L. RANKL-RANK interaction in immune regulatory systems. World J Orthop 2013, 3:142–150.

44. Chang SK, Noss EH, Chen M, Gu Z, Townsend K, Grenha R, Leon L, Lee SY, Lee DM, Brenner MB. Cadherin-11 regulates fibroblast inflammation. Proc Natl Acad Sci U S A 2011, 108:8462–8467.

45. Beilbasakis GN, Reddi D, Bostanci N. Porphyromonas gingivalis induces RANKL in T-cells. Inflammation 2011, 34:133–138.

46. Vander Mierde D, Scheuner D, Quintens R, Patel R, Song B, Tsukamoto K, Beullens M, Kaufman RJ, Bollen M, Schuit FC. Glucose activates a protein phosphatase-1-mediated signaling pathway to enhance overall translation in pancreatic beta-cells. Endocrinology 2007, 148:609–617.

47. Dey S, Baird TD, Zhou D, Palam LR, Spandau DF, Wek RC. Both transcriptional regulation and translational control of ATF4 are central to the integrated stress response. J Biol Chem 2010, 285:33165–33174.

48. Dong Q, Sreekumar PG, Spee C, He S, Ryan SJ, Kannan R, Hinton DR. Deficiency of αβ crystallin augments ER stress-induced apoptosis by enhancing mitochondrial dysfunction. Free Radic Biol Med 2012, 53:1111–1122.

49. Hamaamara K, Tanjung N, Yokota H. Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab 2013; in press.

50. Takayanagi H. The role of NFAT in osteoclast formation. Ann NY Acad Sci 2007, 1116:227–237.

51. He L, Lee J, Jiang J, Salchaki K, Hwang J, Cha-Mohlstad HJ, Kim KA, Ryoo U, Lee HG, Kim SO, Soung NK, Lee KS, Ikwon YT, Erikson RL, Ahn JS, Kim BY. Osteoprosis regulation by salubrinal through eIF2α mediated differentiation of osteoclast and osteoblast. Cell Signal 2013, 25:552–560.

52. Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK, Lee SY, Kim N. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 2007, 109:3253–3259.

53. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Iwashita LB, Takayanagi H. Kamiyo R. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 2009, 15:1066–1071.

54. Miyachi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, Miyamoto K, Hao W, Yoshida S, Morikata H, Chiba K, Kato S, Tokuhisa T, Saitou M, Toyama Y, Suda T, Miyamoto T. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 2010, 207:751–762.